TW201726182A - Method for treating medical waste container - Google Patents
Method for treating medical waste container Download PDFInfo
- Publication number
- TW201726182A TW201726182A TW105138640A TW105138640A TW201726182A TW 201726182 A TW201726182 A TW 201726182A TW 105138640 A TW105138640 A TW 105138640A TW 105138640 A TW105138640 A TW 105138640A TW 201726182 A TW201726182 A TW 201726182A
- Authority
- TW
- Taiwan
- Prior art keywords
- medical waste
- chlorine dioxide
- waste container
- present
- liquid agent
- Prior art date
Links
- 239000002906 medical waste Substances 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 claims abstract description 82
- 229910001919 chlorite Inorganic materials 0.000 claims abstract description 25
- 229910052619 chlorite group Inorganic materials 0.000 claims abstract description 25
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 7
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims description 208
- 239000004155 Chlorine dioxide Substances 0.000 claims description 104
- 235000019398 chlorine dioxide Nutrition 0.000 claims description 104
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 244000005700 microbiome Species 0.000 claims description 40
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 60
- 239000007789 gas Substances 0.000 description 55
- 241000700605 Viruses Species 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 16
- 239000002699 waste material Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 9
- 229960002218 sodium chlorite Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000005507 spraying Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 5
- 235000019799 monosodium phosphate Nutrition 0.000 description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241000714201 Feline calicivirus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- -1 alkali metal chlorite Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 208000030820 Ebola disease Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- KXIGCJSORWZFHJ-UHFFFAOYSA-K Cl(=O)[O-].[Bi+3].Cl(=O)[O-].Cl(=O)[O-] Chemical compound Cl(=O)[O-].[Bi+3].Cl(=O)[O-].Cl(=O)[O-] KXIGCJSORWZFHJ-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 229910001902 chlorine oxide Inorganic materials 0.000 description 1
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Chemical compound ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010808 liquid waste Substances 0.000 description 1
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L11/00—Methods specially adapted for refuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/0075—Disposal of medical waste
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
- B65B55/02—Sterilising, e.g. of complete packages
- B65B55/04—Sterilising wrappers or receptacles prior to, or during, packaging
- B65B55/10—Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B11/00—Oxides or oxyacids of halogens; Salts thereof
- C01B11/02—Oxides of chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/23—Containers, e.g. vials, bottles, syringes, mail
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental & Geological Engineering (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Processing Of Solid Wastes (AREA)
- Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
- Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
Abstract
Description
本發明係有關一種醫療廢棄物容器的處理方法，該醫療廢棄物容器係包含使用含有二氧化氯氣體及亞氯酸鹽之液劑且伴有有害微生物之醫療廢棄物者。 The present invention relates to a method of treating a medical waste container comprising a medical waste using a liquid agent containing chlorine dioxide gas and chlorite and accompanied by harmful microorganisms.
近年來，伊波拉出血熱(ebola hemorrhagic fever)及新型流感等之新出現/重新出現的傳染病在世界各地發生，成為一大問題。該等的傳染病患者所接觸之廢棄物(例如：附著有患者體液的布或衛生紙)，及該等患者用以治療使用之醫療器具(例如：注射器)等，由於可能成為傳染源，故需要適當地作為醫療廢棄物處理。 In recent years, new/re-emerging infectious diseases such as ebola hemorrhagic fever and new influenza have occurred around the world and become a major problem. The wastes (such as cloth or toilet paper to which the patient's body fluid is attached) and the medical devices (such as syringes) used by these patients for treatment purposes may become a source of infection. Properly treated as medical waste.
由於醫療廢棄物可能包含動物所感染的病源體等，故需要在比一般的廢棄物更高度的管理下進行處理。一般而言，醫療廢棄物係經廢棄/保存在專用的醫療廢棄物容器之後，以焚燒或高壓釜等進行滅菌，或由專業者進行回收/處理。然而，在醫療廢棄物容器增殖的病原體、或附著在醫療廢棄物容器之入口附近的病原體朝醫療廢棄物容器外擴散，使得在處理醫療廢棄物容器時受到感染之 風險經常存在。 Since medical waste may contain pathogens infected by animals, it is necessary to handle it under a higher level of management than general waste. In general, medical waste is discarded or stored in a dedicated medical waste container, sterilized by incineration, autoclave, or the like, or recycled/treated by a professional. However, the pathogen that proliferates in the medical waste container or the pathogen attached to the entrance of the medical waste container spreads out of the medical waste container, so that it is infected when the medical waste container is processed. Risks often exist.
在多數的實驗室及醫療機構中，為了使有害微生物失活，係實施以醇系的藥劑擦拭或以噴霧消毒。由於揮發性醇之殺菌能力較低，故在廣泛的醇系藥劑中，使藥液直接接觸對象之微生物者，係在發揮其效果所不可或缺的。亦即，在使用醇系之藥劑的消毒方法中，附著在藥劑無法直接接觸之處的微生物的消毒實為困難(例如：對象為複雜的三維形狀之醫療廢棄物的情形等)。 In most laboratories and medical institutions, in order to inactivate harmful microorganisms, it is wiped with an alcohol-based agent or spray-sterilized. Since the sterilizing ability of the volatile alcohol is low, in a wide range of alcohol-based medicines, it is indispensable for the microorganisms to directly contact the microorganisms of the target. That is, in the sterilization method using an alcohol-based drug, it is difficult to disinfect the microorganisms where the drug cannot be directly contacted (for example, in the case of a medical waste having a complicated three-dimensional shape).
已知二氧化氯氣體在低濃度中係對動物活體為安全的氣體，另一方面，即使在如此低濃度中，對細菌/真菌/病毒等之微生物具有失活作用及除臭作用等特質。至今雖有使用二氧化氯之醫療廢棄物的處理方法提案，然而為了使二氧化氯之消毒效果滲透至醫療廢棄物的各個角落，必須持續地使這些廢棄物暴露於二氧化氯中，因此，必須有大規模的裝置(例如：專利文獻1、專利文獻2)、或必須粉碎醫療廢棄物並浸漬在包含二氧化氯之消毒液中(例如：專利文獻3)等，而缺乏廣泛性。 It is known that chlorine dioxide gas is a safe gas for living animals in a low concentration, and on the other hand, it has an inactivating effect and a deodorizing effect on microorganisms such as bacteria/fungus/virus even at such a low concentration. Although there have been proposals for treatment methods for medical waste using chlorine dioxide, in order to infiltrate the disinfection effect of chlorine dioxide into all corners of medical waste, it is necessary to continuously expose these wastes to chlorine dioxide. It is necessary to have a large-scale apparatus (for example, Patent Document 1 and Patent Document 2), or it is necessary to pulverize medical waste and immerse it in a disinfectant containing chlorine dioxide (for example, Patent Document 3), and the like, and lacks extensiveness.
[專利文獻]日本特開平5-31164 [Patent Document] Japan Special Kaiping 5-31164
[專利文獻]日本特開平8-24324 [Patent Document] Japan Special Kaiping 8-24324
[專利文獻]日本特開平6-39004 [Patent Document] Japan Special Kaiping 6-39004
如上所述，至今尚未提供一種將可能包含有害微生物之醫療廢棄物在醫療廢棄物容器內中進行安全且簡便的處理方法。 As described above, there has not been provided a safe and simple treatment method for medical waste that may contain harmful microorganisms in a medical waste container.
本發明者等，對於包含二氧化氯之溶液的特性進行研究時，將包含二氧化氯氣體及亞氯酸鹽之溶液應用到空間時，出人意料地發現到，相較於以僅溶解有二氧化氯氣體之溶液應用到空間時，空間中的二氧化氯氣體濃度以極長的時間維持之特性(參考本發明之實施例1)。 When the inventors of the present invention studied the characteristics of a solution containing chlorine dioxide, when a solution containing chlorine dioxide gas and chlorite was applied to a space, it was unexpectedly found that compared with only the dissolution of the dioxide When the solution of chlorine gas is applied to the space, the concentration of chlorine dioxide gas in the space is maintained for an extremely long period of time (refer to Example 1 of the present invention).
因此，本發明者等發現，藉由利用包含二氧化氯氣體及亞氯酸鹽之溶液的上述特性，即可將包含醫療廢棄物的醫療廢棄物容器進行簡便且安全的處理，遂而完成本發明。 Therefore, the inventors of the present invention have found that by using the above-described characteristics of a solution containing chlorine dioxide gas and chlorite, the medical waste container containing medical waste can be easily and safely handled, thereby completing the present invention. invention.
亦即，關於本發明之方法，在一實施態樣中，係包含伴有有害微生物之醫療廢棄物的醫療廢棄物容器之處理方法，該方法包含在上述醫療廢棄物容器內應用含有二氧化氯氣體及亞氯酸鹽之液劑的步驟，上述液劑具備將上述二氧化氯氣體徐緩釋出之組成。 That is, with respect to the method of the present invention, in one embodiment, a method of treating a medical waste container containing medical waste associated with harmful microorganisms, the method comprising applying chlorine dioxide in the medical waste container In the step of the gas and the chlorite liquid preparation, the liquid agent has a composition in which the chlorine dioxide gas is slowly released.
而且，本發明之方法，在一實施態樣中，作為前述液劑之組成，係在前述液劑中含有濃度為10至2000ppm之二氧化氯氣體、0.05重量%至10重量%之亞氯酸鹽，且將上述液劑之pH調製在4.5至6.5之範圍內。 Further, in the embodiment of the present invention, as the composition of the liquid agent, the liquid agent contains chlorine dioxide gas at a concentration of 10 to 2000 ppm, and chloric acid at 0.05% by weight to 10% by weight. Salt, and the pH of the above liquid is adjusted to be in the range of 4.5 to 6.5.
而且，本發明之方法，在一實施態樣中， 上述液劑之應用係將前述液劑對醫療廢棄物容器內噴霧、或將包含前述液劑之容器設置在醫療廢棄物容器內者。 Moreover, the method of the present invention, in an embodiment, The application of the above liquid agent is such that the liquid agent is sprayed into a medical waste container or a container containing the liquid agent is placed in a medical waste container.
而且，本發明之方法，在一實施態樣中，前述有害微生物係傳染性微生物。 Moreover, in the method of the present invention, in one embodiment, the aforementioned harmful microorganism is an infectious microorganism.
而且，本發明之方法，在一實施態樣中，前述液劑係包含50至1000ppm之二氧化氯氣體者。 Further, in the method of the present invention, in one embodiment, the liquid agent contains 50 to 1000 ppm of chlorine dioxide gas.
而且，本發明之方法，在一實施態樣中，前述液劑係包含0.1重量%至5.0重量%之亞氯酸鹽者。 Moreover, in the embodiment of the present invention, the liquid preparation comprises 0.1% by weight to 5.0% by weight of chlorite.
而且，本發明之方法，在一實施態樣中，前述液劑之pH在5.5至6.0之範圍內。 Moreover, in the embodiment of the present invention, the pH of the liquid agent is in the range of 5.5 to 6.0.
而且，本發明之方法，在一實施態樣中，前述液劑之應用係對至少部分的前述有害微生物不使前述液劑直接接觸。 Moreover, in a method of the present invention, in one embodiment, the use of the liquid agent is such that at least a portion of the aforementioned harmful microorganisms do not directly contact the liquid agent.
而且，本發明之方法，在一實施態樣中，前述液劑之應用係對所有的前述有害微生物不使前述液劑直接接觸。 Moreover, in the method of the present invention, in one embodiment, the application of the liquid agent does not directly contact the liquid agent with respect to all of the aforementioned harmful microorganisms.
而且，本發明之方法，在一實施態樣中，前述處理係降低前述有害微生物的擴散。 Moreover, in the method of the present invention, in one embodiment, the aforementioned treatment reduces the spread of the aforementioned harmful microorganisms.
另外，上述所列舉之本發明的1個或複數個特徵之任意組合的發明亦包含在本發明之範圍內。 Further, the invention of any combination of one or more of the features of the invention described above is also included in the scope of the invention.
如本申請案之實施例中所示，本發明之方法中使用的液劑應用在醫療廢棄物容器內時，醫療廢棄物內之二氧化氯氣體濃度可長時間的高度保持。因此，根據 本發明之方法，由於醫療廢棄物容器內的醫療廢棄物的各個角落整個暴露於二氧化氯氣體中，故可有效地處理附著於醫療廢棄物之有害微生物，可降低有害微生物自醫療廢棄物容器的擴散。亦即，於本發明之方法，所應用的液劑即使與附著於醫療廢棄物之有害微生物的一部分不直接接觸(或者是，即使所應用的液劑與附著於醫療廢棄物之有害微生物全無直接接觸)，亦可對醫療廢棄物容器內之所有的有害微生物發揮實質性之消毒效果。 As shown in the examples of the present application, when the liquid agent used in the method of the present invention is applied to a medical waste container, the concentration of chlorine dioxide gas in the medical waste can be maintained for a long time. Therefore, according to According to the method of the present invention, since all the corners of the medical waste in the medical waste container are exposed to the chlorine dioxide gas, the harmful microorganisms attached to the medical waste can be effectively treated, and the harmful microorganisms can be reduced from the medical waste container. The spread. That is, in the method of the present invention, the applied liquid agent is not in direct contact with a part of the harmful microorganisms attached to the medical waste (or even if the applied liquid agent and the harmful microorganisms attached to the medical waste are not present at all) Direct contact) can also exert a substantial disinfecting effect on all harmful microorganisms in the medical waste container.
亦即，本發明提供一種將可能包含有害微生物之醫療廢棄物在醫療廢棄物容器中進行安全且簡便的處理之方法。 That is, the present invention provides a method for safely and easily treating medical waste that may contain harmful microorganisms in a medical waste container.
A、B‧‧‧玻璃培養皿 A, B‧‧‧ glass culture dish
第1圖係本申請案之實施例1的試驗之示意圖。 Fig. 1 is a schematic view showing the experiment of Example 1 of the present application.
第2圖係本發明之二氧化氯液劑在腔室內噴霧時，與單純的將二氧化氯氣體溶解液在腔室內噴霧時之腔室內的二氧化氯濃度的經時推移所示之曲線圖。 Fig. 2 is a graph showing the temporal change of the chlorine dioxide concentration in the chamber when the chlorine dioxide solution of the present invention is sprayed in the chamber and the pure chlorine dioxide gas solution is sprayed in the chamber. .
第3圖係本申請案之實施例2的試驗之示意圖。 Figure 3 is a schematic illustration of the experiment of Example 2 of the present application.
第4圖係本申請案之實施例2的試驗中使用之醫療廢棄物容器的照片。 Fig. 4 is a photograph of a medical waste container used in the test of Example 2 of the present application.
第5圖係本申請案之實施例2的試驗之評定方法所示之流程圖。 Fig. 5 is a flow chart showing the evaluation method of the test of Example 2 of the present application.
第6圖係在試驗前及試驗開始60分鐘後的玻璃培養皿A的細菌存活數所示之圖。 Fig. 6 is a graph showing the number of bacterial survival of the glass petri dish A before the test and 60 minutes after the start of the test.
第7圖係在試驗前及試驗開始60分鐘後的玻璃培養皿B的細菌存活數所示之圖。 Fig. 7 is a graph showing the number of bacterial survival of the glass petri dish B before the test and 60 minutes after the start of the test.
第8圖係本申請案之實施例3的實驗簡圖。 Figure 8 is a schematic diagram of the experiment of Example 3 of the present application.
第9圖係本申請案之實施例3的第1次實驗所示結果。 Fig. 9 is a graph showing the results of the first experiment of Example 3 of the present application.
第10圖係本申請案之實施例3的第2次實驗所示結果。 Fig. 10 is a graph showing the results of the second experiment of Example 3 of the present application.
本發明係有關包含伴有有害微生物之醫療廢棄物的醫療廢棄物容器之處理方法。 The present invention relates to a method of treating a medical waste container containing medical waste accompanied by harmful microorganisms.
本說明書中之醫療廢棄物，不限定於有關醫療行為所排出之廢棄物，亦包含可成為傳染病之傳染源的廢棄物。例如：醫療行為所使用之器具(例如：針頭、注射筒、手套、口罩等)、生物實驗所使用的器具(例如：附著微生物的培養皿、培養基、微晶片等)、附著傳染病患者的血液及體液之紙巾或布巾等，亦包含在本說明書中的醫療廢棄物內。 The medical waste in this manual is not limited to wastes discharged from medical activities, but also includes wastes that can be a source of infection for infectious diseases. For example: instruments used for medical activities (eg needles, syringes, gloves, masks, etc.), instruments used in biological experiments (eg, petri dishes with attached microorganisms, culture media, microchips, etc.), blood attached to patients with infectious diseases Paper towels or cloth towels for body fluids are also included in the medical waste in this manual.
本說明書中的醫療廢棄物容器係收納醫療廢棄物之容器，其形狀/構造並無特別限定。從防止傳染性微生物的擴散之觀點，成為本發明之應用對象的醫療廢棄物容器係以氣密性高者為佳，然而即使不是具有完全氣密性，只要是具有某種程度的密閉構造，亦可適當地應用本發明。而且，本發明之方法，只要各個隔室可流體連通，亦可應用在具有複數個隔室之醫療廢棄物容器中(各個隔室非流體連通時，在各個隔室通過本發明之方法的應用， 可得到目的效果)。 The medical waste container in the present specification is a container for storing medical waste, and its shape and structure are not particularly limited. From the viewpoint of preventing the spread of infectious microorganisms, the medical waste container to which the present invention is applied is preferably one having a high airtightness. However, if it is not completely airtight, as long as it has a certain degree of hermetic structure, The present invention can also be suitably applied. Moreover, the method of the present invention can be applied to medical waste containers having a plurality of compartments as long as the compartments are in fluid communication (when the compartments are not in fluid communication, the application of the method of the invention in each compartment) , The purpose of the effect can be obtained).
本發明之方法係包含在醫療廢棄物容器內應用含有二氧化氯氣體及亞氯酸鹽之液劑的步驟。本發明之方法中使用的液劑係以包含濃度為10至2000ppm之二氧化氯氣體、0.05重量%至10重量%之亞氯酸鹽，且上述液劑之pH調製在4.5至6.5之範圍內之液劑為佳。較佳者係液劑中所含的二氧化氯氣體濃度可為50至1000ppm，更佳者可為100至600ppm。而且，較佳者係液劑中所含的亞氯酸鹽之濃度可為0.1重量%至5.0重量%，更佳者可為0.5重量%至2.5重量%。液劑之pH低於4.5時，液劑中的亞氯酸鹽過度反應而釋出二氧化氯氣體，因而難以控制二氧化氯氣體的釋出量，而且，液劑的保存安定性降低。另外，液劑之pH高於6.5時，液劑中的亞氯酸鹽之反應性降低，無法釋出適當量之二氧化氯氣體。液劑之pH以在5.5至6.0之範圍內更佳。另外，液劑中之二氧化氯氣體濃度、亞氯酸鹽濃度及pH係可在上述範圍內任意組合。 The method of the present invention comprises the step of applying a liquid agent containing chlorine dioxide gas and chlorite in a medical waste container. The liquid agent used in the method of the present invention comprises chlorine dioxide gas in a concentration of 10 to 2000 ppm, 0.05% to 10% by weight of chlorite, and the pH of the above liquid agent is adjusted in the range of 4.5 to 6.5. The liquid agent is preferred. Preferably, the chlorine dioxide gas contained in the liquid agent may have a concentration of 50 to 1000 ppm, more preferably 100 to 600 ppm. Further, the concentration of the chlorite contained in the liquid preparation may preferably be from 0.1% by weight to 5.0% by weight, more preferably from 0.5% by weight to 2.5% by weight. When the pH of the liquid agent is less than 4.5, the chlorite in the liquid agent reacts excessively to release the chlorine dioxide gas, so that it is difficult to control the release amount of the chlorine dioxide gas, and the preservation stability of the liquid agent is lowered. Further, when the pH of the liquid agent is higher than 6.5, the reactivity of the chlorite in the liquid agent is lowered, and an appropriate amount of chlorine dioxide gas cannot be released. The pH of the liquid is preferably in the range of 5.5 to 6.0. Further, the chlorine dioxide gas concentration, the chlorite concentration, and the pH system in the liquid agent may be arbitrarily combined within the above range.
本發明之方法中使用的液劑，例如可如下述方式製造。首先，(a)將亞氯酸鹽溶解於水，調製2000至180000ppm之亞氯酸鹽水溶液，(b)使二氧化氯氣體溶解，調製100至2900ppm之二氧化氯水溶液，然後，將(a)及(b)混合之後，在該溶液中，混合pH調整劑作成二氧化氯液劑。另外，上述製造方法中，亞氯酸鹽水溶液之濃度、二氧化氯水溶液之濃度，該技術領域中具有一般知識者可因應目的液劑之組成適當地調整。 The liquid agent used in the method of the present invention can be produced, for example, in the following manner. First, (a) dissolving chlorite in water to prepare an aqueous chlorite solution of 2000 to 180,000 ppm, and (b) dissolving chlorine dioxide gas to prepare an aqueous solution of 100 to 2900 ppm of chlorine dioxide, and then (a And (b) after mixing, a pH adjusting agent is mixed in the solution to prepare a chlorine dioxide solution. Further, in the above production method, the concentration of the chlorite aqueous solution and the concentration of the chlorine dioxide aqueous solution can be appropriately adjusted depending on the composition of the liquid agent in the technical field.
藉由以如上述之方法調整液劑，可將液劑中溶解的二氧化氯濃度自由地從高濃度調整至低濃度。而且，由於本發明中使用的液劑係包含二氧化氯氣體與亞氯酸鹽，故使二氧化氯氣體從液劑釋出至空氣中時，液劑中的二氧化氯氣體濃度會降低，然因化學平衡，二氧化氯自亞氯酸鹽供給至液劑中，其結果，液劑中的二氧化氯氣體濃度大致維持恆定。由此效果，本發明中使用的液劑，可經長時間將二氧化氯氣體徐緩地釋出至空氣中。而且，液劑之pH調製在4.5至6.5之範圍內時，自液劑之二氧化氯氣體的釋出量、與自亞氯酸鹽之二氧化氯的供給之平衡適當地保持，因此，能以更長的時間釋出大致恆定之濃度的二氧化氯氣體。 By adjusting the liquid agent as described above, the concentration of dissolved chlorine dioxide in the liquid agent can be freely adjusted from a high concentration to a low concentration. Further, since the liquid agent used in the present invention contains chlorine dioxide gas and chlorite, the concentration of chlorine dioxide gas in the liquid agent is lowered when chlorine dioxide gas is released from the liquid agent into the air. However, due to chemical equilibrium, chlorine dioxide is supplied from the chlorite to the liquid, and as a result, the concentration of chlorine dioxide gas in the liquid is maintained substantially constant. With this effect, the liquid agent used in the present invention can slowly release chlorine dioxide gas into the air over a long period of time. Further, when the pH of the liquid preparation is in the range of 4.5 to 6.5, the balance between the amount of chlorine dioxide gas released from the liquid agent and the supply of chlorine dioxide from the chlorite is appropriately maintained, and therefore, A substantially constant concentration of chlorine dioxide gas is released over a longer period of time.
本發明之方法中使用的液劑所含的亞氯酸鹽係可列舉例如：亞氯酸鹼金屬鹽及亞氯酸鹼土金屬鹽。亞氯酸鹼金屬鹽係可列舉例如：亞氯酸鈉、亞氯酸鉀及亞氯酸鋰，亞氯酸鹼土金屬鹽係可列舉例如：亞氯酸鈣、亞氯酸鎂及亞氯酸鋇。其中，從取得容易之點，以亞氯酸鈉及亞氯酸鉀為佳，以亞氯酸鈉最佳。該等亞氯酸鹽可單獨使用1種，亦可併用2種以上。 The chlorite contained in the liquid agent used in the method of the present invention may, for example, be an alkali metal chlorite or an alkaline earth metal chlorite. Examples of the alkali metal chlorite salt include sodium chlorite, potassium chlorite, and lithium chlorite. Examples of the alkaline earth metal chlorite include calcium chlorite, magnesium chlorite, and bismuth chlorite. . Among them, sodium chlorite and potassium chlorite are preferred, and sodium chlorite is preferred from the point of view of ease. These chlorites may be used alone or in combination of two or more.
用以調製本發明之方法中使用的液劑的pH調整劑，在該技術領域中具有一般知識者係可使用任意者，惟可使用例如：磷酸、硼酸、偏磷酸、焦磷酸、胺磺酸、乙酸、檸檬酸及該等之鹽等，在可得優異之保存安定性之觀點上，係以無機酸或其鹽為佳。其中，從保存安定 性優異，可將保存中之液性(pH)的變動控制到最小，由此即可發揮優異之殺菌作用、抗病毒作用、防霉作用及防臭作用等之效果之觀點，係以使用磷酸或其鹽(例如：磷酸二氫鈉、磷酸二氫鈉與磷酸氫二鈉之混合物等)者為佳，以使用磷酸二氫鈉者更佳。另外，pH調整劑可單獨使用1種，亦可併用2種以上。 The pH adjuster used to prepare the liquid agent used in the method of the present invention can be used by any person having ordinary knowledge in the art, but for example, phosphoric acid, boric acid, metaphosphoric acid, pyrophosphoric acid, amine sulfonic acid can be used. Acetic acid, citric acid, and the like are preferably inorganic acids or salts thereof from the viewpoint of obtaining excellent storage stability. Among them, from the preservation of stability Excellent in properties, it can control the change of liquidity (pH) during storage to a minimum, and thus can exert the effects of excellent bactericidal action, antiviral action, antifungal action and deodorization effect, etc., using phosphoric acid or The salt (for example, sodium dihydrogen phosphate, a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate, etc.) is preferred, and those using sodium dihydrogen phosphate are more preferred. Further, the pH adjuster may be used singly or in combination of two or more.
本發明之方法中，液劑應用在醫療廢棄物容器內的方法為任意，例如；可藉由將上述液劑在醫療廢棄物容器內噴霧來應用，而且，亦可為藉由將包含上述液劑之容器設置在醫療廢棄物容器內來應用。經由應用立即發揮效果，且該效果可持續較長的時間之觀點上，以液劑經噴霧之應用更佳。 In the method of the present invention, the method of applying the liquid agent in the medical waste container is arbitrary, for example, the liquid agent can be applied by spraying the liquid medicine in the medical waste container, and the liquid can be contained by the liquid. The container of the agent is placed in a medical waste container for application. The application of the liquid agent by spraying is more preferable from the viewpoint that the effect is immediately exerted by the application and the effect can be sustained for a long period of time.
而且，亦如本申請案之實施例中所示者，本發明之方法中使用的液劑應用在醫療廢棄物容器內時，醫療廢棄物內之二氧化氯氣體濃度可長時間的高度保持。因此，根據本發明之方法，醫療廢棄物容器內的醫療廢棄物的各個角落整個係暴露於二氧化氯氣體中，因此可有效地處理附著於醫療廢棄物的有害微生物，可降低有害微生物自醫療廢棄物容器的擴散。亦即，於本發明之方法中，所應用的液劑即使與附著於醫療廢棄物之有害微生物的一部分不直接接觸(或者是，即使所應用的液劑與附著於醫療廢棄物之有害微生物全無直接接觸)，亦可對醫療廢棄物容器內之所有的有害微生物發揮實質性的消毒效果。 Moreover, as also shown in the examples of the present application, when the liquid agent used in the method of the present invention is applied to a medical waste container, the concentration of chlorine dioxide gas in the medical waste can be maintained for a long time. Therefore, according to the method of the present invention, all corners of the medical waste in the medical waste container are exposed to chlorine dioxide gas as a whole, so that harmful microorganisms attached to medical waste can be effectively treated, and harmful microorganisms can be reduced from medical treatment. The spread of waste containers. That is, in the method of the present invention, the applied liquid agent is not in direct contact with a part of the harmful microorganisms attached to the medical waste (or even if the applied liquid agent and the harmful microorganisms attached to the medical waste are all It can also exert substantial disinfection effect on all harmful microorganisms in medical waste containers without direct contact.
本發明之方法中之有害微生物係廣泛地包 含可對人或動物造成不良影響之微生物，尤其是，包含對人或動物具有傳染性之微生物。例如：本發明中之有害微生物係包含：病毒、細菌、真菌、古細菌及寄生物(例如：寄生蟲、寄生性之節肢動物)、感染性之蛋白質(例如：變異性朊蛋白(Abnormal prion protein))。可應用本發明之方法的病毒方面，可列舉如：具包膜的病毒或不具包膜的病毒，例如：水痘/帶狀皰疹病毒、流感病毒(人、鳥及豬等)、單純疱疹型病毒、腺病毒、腸病毒、鼻病毒、人類乳突病毒(人類乳頭瘤病毒)、痘病毒、柯薩奇病毒、單純疱疹型病毒(HSV：herpes simplex virus)、巨細胞病毒、EB病毒、腺病毒、乳突狀瘤病毒、JC病毒、微小病毒、B型肝炎病毒、C型肝炎病毒、賴薩病毒、貓杯狀病毒、諾羅病毒、沙波病毒、冠狀病毒、SARS病毒、風疹病毒、腮腺炎病毒、麻疹病毒、RS病毒、脊髓灰白質炎病毒、柯薩奇病毒、埃可病毒、馬爾堡病毒、伊波拉病毒、黃熱病病毒、本揚維拉病毒科病毒、狂犬病病毒、裏奧病毒科病毒、輪狀病毒、人類免疫缺乏病毒(HIV)、人類T淋巴細胞白血病病毒、猿猴免疫缺乏病毒及STLV等。而且，可應用本發明之方法的細菌係有革蘭氏陽性菌或革蘭氏陰性菌，可列舉例如：金黃色葡萄球菌、綠膿桿菌、大腸桿菌、鏈球菌、淋病雙球菌、梅毒菌、腦膜炎雙球菌、結核桿菌、抗酸菌、克萊桿菌(肺炎桿菌)、沙氏桿菌、肉毒桿菌、變形桿菌、百日咳嗜血桿菌、沙雷氏菌、腸炎弧菌、檸檬酸桿菌、不動桿菌、曲狀桿菌、腸桿菌、黴漿菌、披衣菌及梭孢桿菌 等。更且，可應用本發明之方法的真菌，可列舉例如：麴菌、髮癬菌、馬拉色菌(Malassezia fungi)及念珠菌等。 The harmful microorganisms in the method of the present invention are widely packaged Containing microorganisms that can adversely affect humans or animals, in particular, microorganisms that are infectious to humans or animals. For example, the harmful microorganisms in the present invention include: viruses, bacteria, fungi, archaea and parasites (for example, parasites, parasitic arthropods), infectious proteins (for example, Abnormal prion protein). )). Examples of the virus to which the method of the present invention can be applied include, for example, an enveloped virus or a non-enveloped virus, for example, varicella/zoster virus, influenza virus (human, bird, pig, etc.), herpes simplex type. Virus, adenovirus, enterovirus, rhinovirus, human papillomavirus (human papillomavirus), poxvirus, coxsackie virus, herpes simplex virus (HSV: herpes simplex virus), cytomegalovirus, EB virus, gland Virus, papilloma virus, JC virus, parvovirus, hepatitis B virus, hepatitis C virus, raisa virus, cat calicivirus, norovirus, sand wave virus, coronavirus, SARS virus, rubella virus, Mumps virus, measles virus, RS virus, poliovirus, coxsackie virus, echovirus, Marburg virus, Ebola virus, yellow fever virus, Benjana virus virus, rabies virus, rio Viral virus, rotavirus, human immunodeficiency virus (HIV), human T lymphocytic leukemia virus, simian immunodeficiency virus, and STLV. Further, the bacteria to which the method of the present invention can be applied are Gram-positive bacteria or Gram-negative bacteria, and examples thereof include Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Gonococci, and syphilis, Meningococcal, Mycobacterium tuberculosis, acid-fast bacteria, Klebsiella (Klebsiella pneumoniae), Salmonella, Botox, Proteus, Haemophilus pertussis, Serratia, Vibrio cholerae, Citrobacter, not moving Bacillus, Aspergillus, Enterobacter, Mycoplasma, Chlamydia and Clostridium Wait. Further, examples of the fungus to which the method of the present invention can be applied include, for example, sputum, sputum, Malassezia fungi, and Candida.
本說明書中使用之術語係用以說明特定的實施態樣而使用，並不意在限制本發明。 The terms used in the specification are used to describe specific embodiments and are not intended to limit the invention.
另外，本說明書中使用之「包含」的術語，除非是在文中有明顯不同的解讀之外，旨在所記載之事項(構件、步驟、要件或數字等)均存在，而不排除其它事項(構件、步驟、要件或數字等)的存在。 In addition, the term "comprising" as used in this specification is intended to mean that the recited items (components, steps, elements, figures, etc.) are present, unless otherwise stated. The existence of components, steps, requirements or numbers, etc.).
除非有不同的定義，此處所使用之所有的術語(包含技術術語及科學術語)係指與由本發明所屬技術領域中具有一般知識者所能廣泛理解者相同之意。此處所使用之術語，除非出現不同的定義，均解讀為具有與本說明書及相關技術領域中之含義一致之意，不應解讀為理想化或過度形式化之意。 Unless otherwise defined, all terms (including technical and scientific terms) used herein are intended to mean the same as the one of ordinary skill in the art. Terms used herein are to be interpreted as having the meaning consistent with the present specification and the related art, and should not be interpreted as idealized or over-formal.
本發明之實施態樣係有參照示意圖說明的情形，示意圖中，為了說明清楚，會有誇大描述的情形。 The embodiments of the present invention are described with reference to the drawings, and in the drawings, for the sake of clarity, the description will be exaggerated.
本說明書中，例如表示「1至10%」時，所屬技術領域中具有一般知識者對該表示應可理解為單獨且具體地指出1、2、3、4、5、6、7、8、9或10%。 In the present specification, for example, when "1 to 10%" is indicated, those having ordinary knowledge in the art should be understood as being individually and specifically indicating 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10%.
本說明書中，呈示成分含量及數值範圍中所使用之任意數值，除非另有明確說明，應解讀為包含術語「約」之意。例如：「10倍」，除非另有明確說明，應解讀為「約10倍」之意。 In the present specification, any numerical value used in the range of the content of the present invention and the numerical value range, unless explicitly stated otherwise, should be construed as including the term "about". For example: "10 times", unless otherwise stated, should be interpreted as "about 10 times".
本說明書中所引用之文獻，該等之所有揭 示應視為本說明書中之援用，所屬技術領域中具有一般知識者，依據本說明書之上下文，在不脫離本發明之精神及範圍的前提下，應理解該等之先前技術文獻中的相關揭示內容係援用作為本說明書的部分內容。 The documents cited in this manual, all of which are disclosed The present invention is to be understood as being used in the present specification, and those skilled in the art will understand the relevant disclosures in the prior art documents in the context of the present disclosure without departing from the spirit and scope of the present invention. The content is used as part of this specification.
以下，參照實施例以更詳細說明本發明。然而，本發明係可通過各種樣態具體實施，不應解讀為限定於其中所記載之實施例。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention may be embodied in various forms and should not be construed as being limited to the embodiments described.
實施例1：本發明之二氧化氯液劑之空間中的二氧化氯濃度持續效果 Example 1: Continuous effect of chlorine dioxide concentration in the space of the chlorine dioxide solution of the present invention
本發明之二氧化氯液劑係如下調製。首先，在亞氯酸鈉25重量%溶液500ml中加入水17L，調製成亞氯酸鈉水溶液。然後，調製經溶解二氧化氯氣體2000ppm之二氧化氯水溶液1000ml，再與上述亞氯酸鈉水溶液混合、攪拌。接著，加入使該溶液之pH成為5.5至6.0之量的磷酸二氫鈉及水之後加以攪拌。進行如此操作，得到包含二氧化氯氣體、亞氯酸鈉及磷酸二氫鈉之二氧化氯液劑20L(亦即，得到包含亞氯酸鈉0.625重量%、二氧化氯氣體100ppm且pH為5.5至6.0之液劑)。本實施例中，該二氧化氯液劑稱為「本發明之二氧化氯液劑」。 The chlorine dioxide solution of the present invention is prepared as follows. First, 17 L of water was added to 500 ml of a 25 wt% sodium chlorite solution to prepare an aqueous sodium chlorite solution. Then, 1000 ml of a chlorine dioxide aqueous solution of 2000 ppm of dissolved chlorine dioxide gas was prepared, and the mixture was mixed with the above aqueous sodium chlorite solution and stirred. Next, sodium dihydrogen phosphate and water in which the pH of the solution is adjusted to 5.5 to 6.0 are added, followed by stirring. By doing so, 20 L of a chlorine dioxide solution containing chlorine dioxide gas, sodium chlorite and sodium dihydrogen phosphate is obtained (that is, 0.625% by weight of sodium chlorite, 100 ppm of chlorine dioxide gas, and pH 5.5 are obtained. Liquid to 6.0). In the present embodiment, the chlorine dioxide liquid agent is referred to as "the chlorine dioxide liquid of the present invention".
本實施例中，作為比較例使用之二氧化氯氣體溶解液係，藉由在亞氯酸鈉中通過鹽酸的加入所產生之二氧化氯氣體溶解於水而調製(亦即，單純地使二氧化氯 氣體溶解於水之溶液)。本實施例中，該溶液稱為「二氧化氯氣體溶解液」。 In the present embodiment, the chlorine dioxide gas solution used as a comparative example is prepared by dissolving chlorine dioxide gas generated by the addition of hydrochloric acid in sodium chlorite in water (that is, simply making two Chlorine oxide The gas is dissolved in a solution of water). In the present embodiment, the solution is referred to as "chlorine dioxide gas solution".
第1圖呈示本實施例之實驗概要。準備1m3之腔室，將本發明之二氧化氯液劑或二氧化氯氣體溶解液經噴霧器進行3次噴霧。一面通過2個風扇攪拌腔室內之空氣，同時以氣體檢測器經時性地測定腔室內之二氧化氯氣體濃度。 Figure 1 presents an outline of the experiment of this embodiment. A chamber of 1 m 3 was prepared, and the chlorine dioxide solution or the chlorine dioxide gas solution of the present invention was sprayed three times through a sprayer. While stirring the air in the chamber through two fans, the concentration of chlorine dioxide gas in the chamber was measured with a gas detector over time.
實驗結果呈示於第2圖。如第2圖所示，將二氧化氯氣體溶解液進行噴霧時，二氧化氯氣體濃度迅速地減少，經1.5小時後，小於檢測極限。另一方面，將本發明之二氧化氯液劑進行噴霧時，在約2小時之內仍舊維持氣體濃度，其後徐緩地減少，在8小時後仍維持有初期濃度的約40%。 The experimental results are presented in Figure 2. As shown in Fig. 2, when the chlorine dioxide gas solution was sprayed, the chlorine dioxide gas concentration rapidly decreased, and after 1.5 hours, it was less than the detection limit. On the other hand, when the chlorine dioxide solution of the present invention was sprayed, the gas concentration was maintained for about 2 hours, and then slowly decreased, and about 40% of the initial concentration was maintained after 8 hours.
亦即，令人驚奇的是，本發明之二氧化氯液劑在空間中噴霧時，在該空間，呈現具有極長時間維持二氧化氯氣體濃度的特性。 That is, it is surprising that the chlorine dioxide solution of the present invention exhibits a characteristic of maintaining a concentration of chlorine dioxide gas for a very long time in the space when it is sprayed in a space.
實施例2：利用本發明之二氧化氯液劑之醫療廢棄物容器內的微生物之殺菌 Example 2: Sterilization of microorganisms in a medical waste container using the chlorine dioxide solution of the present invention
第3圖呈示本實施例之實驗概要。而且，本實施例中所使用之二氧化氯液劑係以與實施例1記載之相同方法調製的二氧化氯液劑。 Figure 3 presents an outline of the experiment of this embodiment. Further, the chlorine dioxide liquid used in the present Example was a chlorine dioxide liquid prepared in the same manner as described in Example 1.
首先，準備醫院等使用之醫療用廢棄物之容器(40L)(第4圖)，在該容器中央設有分格區(至容器高度的2/3)。在一個分格區設置面朝上之附著有大腸桿菌之培養皿(設置A)，另一區設置面朝下之相同的培養皿(設置B)。將83%乙醇或本發明之二氧化氯液劑朝設置A之培養皿噴霧，1小時後，自設置A及設置B之培養皿回收大腸桿菌，按照常規方法測定活菌數。評定方法之概要呈示於第5圖。 First, a container (40L) for medical waste used in a hospital or the like (Fig. 4) is prepared, and a compartment (to 2/3 of the height of the container) is provided in the center of the container. In a compartment, set the petri dish with E. coli (face A) with the face up and the same dish with the face down (set B). 83% ethanol or the chlorine dioxide solution of the present invention was sprayed to the Petri dish set A. After 1 hour, Escherichia coli was recovered from the culture dish in which A and B were set, and the viable cell count was measured according to a conventional method. A summary of the assessment method is presented in Figure 5.
實驗結果呈示於第6圖及第7圖。如第6圖及第7圖所示，在設置A中，83%乙醇、本發明之二氧化氯液劑均使大腸桿菌失活，而在設置B(噴霧區之相反區)中，僅本發明之二氧化氯液劑可使大腸桿菌失活。將二氧化氯液劑噴霧時之容器內的二氧化氯氣體濃度為3.3ppm。其結果係暗示自噴霧之二氧化氯液劑產生二氧化氯氣體，通過該氣體使遠處設置成面朝下之大腸桿菌失活。 The experimental results are presented in Figures 6 and 7. As shown in Fig. 6 and Fig. 7, in setting A, 83% ethanol and the chlorine dioxide solution of the present invention all inactivate Escherichia coli, and in setting B (the opposite zone of the spray zone), only The chlorine dioxide solution of the invention can inactivate E. coli. The concentration of chlorine dioxide gas in the container when the chlorine dioxide solution was sprayed was 3.3 ppm. As a result, it is suggested that chlorine dioxide gas is generated from the chlorine dioxide solution sprayed, and the Escherichia coli which is disposed to face downward is inactivated by the gas.
亦即，根據本發明之二氧化氯液劑，不僅可將直接應用液劑之處的微生物進行消毒，由於應用液劑之容器內的二氧化氯濃度歷經長期間仍維持效果，因而亦可至不直接應用液劑之處(例如：液劑未直接到達之容器的角落及複雜構造之廢棄物的各個角落)進行消毒。而且，根據本發明之二氧化氯液劑，即使不直接應用在成為消毒對象之醫療廢棄物，只要液劑應用在收納有醫療廢棄物之容器的特定空間，即可間接地對醫療廢棄物之各個角落發揮 消毒效果，因此，可提供一種使從事醫療者等接觸醫療廢棄物之風險降到最低之消毒方法。 That is, according to the chlorine dioxide solution of the present invention, not only the microorganisms directly applied to the liquid agent can be sterilized, but also the concentration of chlorine dioxide in the container for applying the liquid agent can maintain the effect over a long period of time, and thus Disinfection is not carried out where the liquid is not applied directly (for example, the corners of the container where the liquid does not reach directly and the corners of the waste of complex construction). Further, according to the chlorine dioxide solution of the present invention, even if it is not directly applied to the medical waste to be disinfected, the liquid waste can be indirectly applied to the medical waste as long as it is applied to a specific space in which the medical waste container is stored. Play in every corner The disinfecting effect, therefore, provides a method of disinfecting that minimizes the risk of medical personnel being exposed to medical waste.
例如：新型流感、伊波拉出血熱及MERS等的致死率高的傳染病在流行時，預測在短期間內將有疑似附有傳染源之廢棄物大量產生。將本發明之方法應用在收納該等廢棄物之容器等時，可將傳染源以更簡便且安全地封堵(或者，可使有害微生物自廢棄物容器擴散之風險降低)。 For example, when infectious diseases with high mortality rates such as new influenza, Ebola hemorrhagic fever and MERS are in prevailing, it is predicted that a large amount of waste suspected of being infected with a source of infection will be produced in a short period of time. When the method of the present invention is applied to a container or the like for accommodating such wastes, the source of infection can be more easily and safely blocked (or the risk of spreading harmful microorganisms from the waste container can be reduced).
實施例3：利用本發明之二氧化氯液劑之醫療廢棄物容器內的病毒之失活 Example 3: Inactivation of virus in a medical waste container using the chlorine dioxide solution of the present invention
試驗病毒：貓杯狀病毒(feline calicivirus,FCV,F9,ATCC VR-782)(作為取代諾羅病毒使用) Test virus: feline calicivirus (FCV, F9, ATCC VR-782) (used as a substituted norovirus)
宿主細胞：克蘭德爾裡斯貓腎細胞(Crandell Rees feline kidney cells)(CRFK,ATCC,CCL-94) Host cells: Crandell Rees feline kidney cells (CRFK, ATCC, CCL-94)
二氧化氯氣體產生源：以與實施例1所記載之相同方法調製的二氧化氯液劑 Chlorine dioxide gas generation source: chlorine dioxide solution prepared in the same manner as described in Example 1.
實驗器具 Laboratory equipment
‧1m3腔室(訂購物) ‧1m 3 chamber (ordered)
‧96孔微量滴定板(353072,FALCON) ‧96-well microtiter plate (353072, FALCON)
‧96孔深孔板(BM6030,BM Bio) ‧96 hole deep well plate (BM6030, BM Bio)
‧試劑儲存容器/Tip-Tub(022265806,eppendorf) ‧Reagent storage container/Tip-Tub (022265806, eppendorf)
‧AC風扇(MU 825S-13N,ORIX) ‧AC fan (MU 825S-13N, ORIX)
‧玻璃培養皿(305-02,Top) ‧ glass culture dish (305-02, Top)
‧細胞刮刀(179693,Thermo) ‧cell scraper (179693, Thermo)
‧氣體檢測器(編號23L二氧化氯，GASTEC) ‧Gas detector (No. 23L chlorine dioxide, GASTEC)
實驗機器 Experimental machine
‧CO2培養箱(MCO-175 AICUVH,PANASONIC) ‧CO 2 incubator (MCO-175 AICUVH, PANASONIC)
‧溫濕度計(TR-72 wf,T&D) ‧Temperature and Hygrometer (TR-72 wf, T&D)
實驗材料 Experimental Materials
‧DMEM高葡萄糖(Dulbecco’s Modified Eagle’s Medium-high glucose,D-MEM,D 5796,SIGMA) ‧DMEM high glucose (Dulbecco's Modified Eagle’s Medium-high glucose, D-MEM, D 5796, SIGMA)
‧杜伯科氏磷酸鹽緩衝鹽水(Dulbecco’s Phosphate Buffered Saline,D8537,SIGMA) ‧Dulbecco’s Phosphate Buffered Saline, D8537, SIGMA
‧0.25%胰蛋白酶溶液(0.25% Trypsin Solution,35555-54,NACALAI TESQUE) ‧0.25% trypsin solution (0.25% Trypsin Solution, 35555-54, NACALAI TESQUE)
‧胎牛血清(Fetal Bovine Serum,FBS,30-2020,ATCC) ‧ fetal bovine serum (Fetal Bovine Serum, FBS, 30-2020, ATCC)
‧在PBS鹽水之EDTA二鈉鹽2%溶液(2820549,MP) ‧ 2% solution of EDTA disodium salt in PBS saline (2820549, MP)
病毒浮游液之調整： Adjustment of virus floating liquid:
將凍存至-80℃之貓杯狀病毒(Feline calicivirus)(108.5TCID50/50μL)以1%FBS溶液稀釋至107-7.5TCID50/50μL者作為病毒浮游液。 Feline calicivirus (10 8.5 TCID 50 /50 μL) frozen to -80 ° C was diluted to 10 7-7.5 TCID 50 /50 μL in 1% FBS solution as a virus floating solution.
病毒回收液(中和液)： Virus recovery solution (neutralization solution):
將含有1mM硫代硫酸鈉溶液(*)之2%FBS D-MEM(抗+)120μL作為病毒回收液。 120 μL of 2% FBS D-MEM (anti-+) containing 1 mM sodium thiosulfate solution (*) was used as a virus recovery solution.
(*)1mM硫代硫酸鈉溶液係可毫無問題地將0.1ppmv之二氧化氯氣體中和之濃度。 (*) A 1 mM sodium thiosulfate solution is a concentration that neutralizes 0.1 ppmv of chlorine dioxide gas without any problem.
實驗方法(參照第8圖)： Experimental method (refer to Figure 8):
將滴入1μl之添加有1%FBS(胎牛血清)的貓杯狀病毒浮游液(107-7.5TCID50/50μL)的培養皿設置在1m3腔室內的B的位置。設置後，將本發明之二氧化氯液劑在離所設置之培養皿約70cm處噴霧。使滴入之FCV，經以本發明之二氧化氯液劑噴霧所產生之二氧化氯氣體在各時間暴露而中和後，回收病毒，求得各時間的病毒感染力價(Virus Infectivity Titer)並加以評定。同樣地，以水取代本發明之二氧化氯液劑噴霧者作為對照組。 A Petri dish containing 1 μl of cat calicivirus floating solution (10 7-7.5 TCID 50 / 50 μL) supplemented with 1% FBS (fetal calf serum) was placed in the position of B in a 1 m 3 chamber. After the setting, the chlorine dioxide solution of the present invention was sprayed at about 70 cm from the set culture dish. After instilling the FCV, the chlorine dioxide gas generated by the chlorine dioxide solution spray of the present invention is neutralized at each time and neutralized, and the virus is recovered to obtain the virus infectivity Titer at each time. And assessed. Similarly, the chlorine dioxide solution spray of the present invention was replaced with water as a control group.
二氧化氯氣體濃度： Chlorine dioxide gas concentration:
1m3腔室內之二氧化氯氣體濃度係經由檢測管測定。 The concentration of chlorine dioxide gas in the chamber of 1 m 3 was measured via a test tube.
實驗係進行2次。 The experiment was performed twice.
第1次之實驗結果呈示於第9圖。第1次之實驗中，將本發明之二氧化氯液劑噴霧時，腔室內之二氧化氯氣體濃度平均為0.1ppmv(最小值：0.075ppmv、最大值：0.1ppmv)。在以水取代本發明之二氧化氯液劑噴霧的對照組中，噴霧10分鐘後之病毒力價為106.3TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為102.8TCID50/50μL(減少3.5log10)。而且，噴霧15分鐘之後，對照組中之病毒力價為104.5TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為102.3TCID50/50μL(減少2.2log10)。噴霧30分鐘之後，對照組中之病毒力價為105.5TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為101.0TCID50/50μL(減少4.5log10)。 The results of the first experiment are shown in Figure 9. In the first experiment, when the chlorine dioxide solution of the present invention was sprayed, the concentration of chlorine dioxide gas in the chamber was 0.1 ppmv (minimum value: 0.075 ppmv, maximum value: 0.1 ppmv). In the control group in which the chlorine dioxide solution spray of the present invention was replaced by water, the viral power after spraying for 10 minutes was 10 6.3 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 2.8. TCID 50 /50 μL (reduced by 3.5 log 10 ). Further, after 15 minutes of spraying, the viral power in the control group was 10 4.5 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 2.3 TCID 50 /50 μL (2.2 log 10 reduction). After 30 minutes of spraying, the viral power in the control group was 10 5.5 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 1.0 TCID 50 /50 μL (4.5 log 10 reduction).
第2次之實驗結果呈示於第10圖。第2次之實驗中，將本發明之二氧化氯液劑噴霧時，腔室內之二氧化氯氣體濃度平均為0.1ppmv(最小值：0.1ppmv、最大值：0.2ppmv)。在以水取代本發明之二氧化氯液劑噴霧的對照組中，噴霧10分鐘後之病毒力價為105.5TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為100.8TCID50/50μL(減少4.7log10)。而且，噴霧15分鐘之後，對照組中之病毒力價為104.3TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為101.7TCID50/50μL(減少2.6log10)。噴霧30分鐘之後，對照組中之病毒力價為103.9TCID50/50μL，惟將本發明之二氧化氯液劑噴霧時，成為100.5TCID50/50μL(減少3.4log10) The results of the second experiment are shown in Figure 10. In the second experiment, when the chlorine dioxide solution of the present invention was sprayed, the concentration of chlorine dioxide gas in the chamber was 0.1 ppmv on average (minimum value: 0.1 ppmv, maximum value: 0.2 ppmv). In the control group in which the chlorine dioxide solution spray of the present invention was replaced by water, the viral power after spraying for 10 minutes was 10 5.5 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 0.8. TCID 50 /50μL (4.7log 10 reduction). Further, after 15 minutes of spraying, the viral power in the control group was 10 4.3 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 1.7 TCID 50 /50 μL (reduced by 2.6 log 10 ). After 30 minutes of spraying, the viral power in the control group was 10 3.9 TCID 50 /50 μL, but when the chlorine dioxide solution of the present invention was sprayed, it became 10 0.5 TCID 50 /50 μL (reduced by 3.4 log 10 )
由以上所述，證明本發明不僅可用於細菌，亦適用於病毒。 From the above, it was confirmed that the present invention can be applied not only to bacteria but also to viruses.
Claims (10)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015-232008 | 2015-11-27 | ||
| JP2015232008 | 2015-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201726182A true TW201726182A (en) | 2017-08-01 |
| TWI795348B TWI795348B (en) | 2023-03-11 |
Family
ID=58763470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111115846A TW202233258A (en) | 2015-11-27 | 2016-11-24 | Method for treating medical waste container |
| TW105138640A TWI795348B (en) | 2015-11-27 | 2016-11-24 | Method for treating medical waste container before disposal |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111115846A TW202233258A (en) | 2015-11-27 | 2016-11-24 | Method for treating medical waste container |
Country Status (6)
| Country | Link |
|---|---|
| JP (2) | JPWO2017090570A1 (en) |
| KR (1) | KR102601062B1 (en) |
| CN (1) | CN108367091A (en) |
| HK (1) | HK1252261A1 (en) |
| TW (2) | TW202233258A (en) |
| WO (1) | WO2017090570A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113660960B (en) * | 2019-04-04 | 2023-12-12 | 霓达株式会社 | Pollution removal device and system |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190725A (en) * | 1990-04-19 | 1993-03-02 | Winfield Industries | Chemical treatment of an infectious waste |
| JPH08129B2 (en) | 1991-07-29 | 1996-01-10 | 藤田 佐内 | Medical waste treatment method |
| JP3345049B2 (en) | 1992-07-22 | 2002-11-18 | 義昭 波多野 | Medical waste treatment method and apparatus therefor |
| JP3492423B2 (en) | 1994-07-19 | 2004-02-03 | 佐内 藤田 | Method and apparatus for sterilizing and deodorizing medical waste |
| JP3110724B2 (en) * | 1997-11-28 | 2000-11-20 | ビジネスプラン株式会社 | Pure chlorine dioxide solution, gel composition and foamable composition containing the same, and container for containing them |
| JP2000063217A (en) * | 1998-06-11 | 2000-02-29 | Dmc Network:Kk | Sustained release chlorine dioxide-containing liquid agent having excellent preservation stability |
| JP2001029440A (en) * | 1999-07-21 | 2001-02-06 | San Seal:Kk | Sterilizing/deodorizing method for repeatedly used medical instrument, clothing or the like |
| KR100816333B1 (en) * | 2001-08-30 | 2008-03-24 | 삼성전자주식회사 | Color filter plate and thin film transistor plate for liquid crystal display, and methods for fabricating the plates |
| JP2006263173A (en) * | 2005-03-24 | 2006-10-05 | San Seal:Kk | Device for generating high concentration germicidal gas, and circulation type sterilizing method with the germicidal gas |
| CN104770394A (en) * | 2007-03-15 | 2015-07-15 | 大幸药品株式会社 | Pure chlorine dioxide solution, and gel-like composition and foaming composition each comprising the same |
| EP2130795A4 (en) * | 2007-03-15 | 2012-12-19 | Taiko Pharmaceutical Co Ltd | Composition for stabilizing chlorine dioxide |
-
2016
- 2016-11-21 CN CN201680068097.7A patent/CN108367091A/en active Pending
- 2016-11-21 WO PCT/JP2016/084516 patent/WO2017090570A1/en active Application Filing
- 2016-11-21 KR KR1020187014252A patent/KR102601062B1/en active IP Right Grant
- 2016-11-21 JP JP2017552409A patent/JPWO2017090570A1/en active Pending
- 2016-11-24 TW TW111115846A patent/TW202233258A/en unknown
- 2016-11-24 TW TW105138640A patent/TWI795348B/en active
-
2018
- 2018-09-07 HK HK18111565.2A patent/HK1252261A1/en unknown
-
2020
- 2020-12-22 JP JP2020212017A patent/JP7204232B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180088810A (en) | 2018-08-07 |
| JPWO2017090570A1 (en) | 2018-09-13 |
| TWI795348B (en) | 2023-03-11 |
| JP7204232B2 (en) | 2023-01-16 |
| CN108367091A (en) | 2018-08-03 |
| TW202233258A (en) | 2022-09-01 |
| JP2021045753A (en) | 2021-03-25 |
| HK1252261A1 (en) | 2019-05-24 |
| KR102601062B1 (en) | 2023-11-10 |
| WO2017090570A1 (en) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhardwaj et al. | UVC-based photoinactivation as an efficient tool to control the transmission of coronaviruses | |
| JP6877387B2 (en) | Stabilized hypochlorous acid solution | |
| Quevedo et al. | Inactivation of Coronaviruses in food industry: The use of inorganic and organic disinfectants, ozone, and UV radiation | |
| JP6055861B2 (en) | Airborne virus countermeasures | |
| Kindermann et al. | Virus disinfection for biotechnology applications: Different effectiveness on surface versus in suspension | |
| Krishnan et al. | Evaluation of a dry fogging system for laboratory decontamination | |
| Gregersen et al. | Inactivation of stable viruses in cell culture facilities by peracetic acid fogging | |
| US10471165B2 (en) | Sterilization or disinfection of workpieces, including medical and dental instruments | |
| Rowan et al. | Efficacy of frontline chemical biocides and disinfection approaches for inactivating SARS-CoV-2 variants of concern that cause coronavirus disease with the emergence of opportunities for green eco-solutions | |
| JP7204232B2 (en) | How to dispose of medical waste containers | |
| KR20200071200A (en) | Compositions for sterilization and disinfection using hydrogen peroxide | |
| JP2016101304A (en) | Removal method of viruses or bacteria and removal device of viruses or bacteria | |
| Yee et al. | Efficacy of chlorine dioxide as a disinfectant | |
| Leanse et al. | Shedding UVC light on Covid-19 to protect dentistry staff and patients | |
| Sharma et al. | Achieving sterility in biomedical and pharmaceutical products (part-I): thermal, chemical, and filtration sterilization | |
| JP2008214297A (en) | Antiviral agent | |
| Barnes et al. | Action of physical and chemical agents on microorganisms | |
| Sanofer | Glass Bead Steriliser Used As Chair Side Sterilisation in the Dentistry-A Research Article | |
| Parija | Sterilisation and Disinfection | |
| Narang et al. | Infection control in dentistry: A review | |
| Bocklagea et al. | Evaluation of Hypochlorous Acid Fogging: An Alternative Disinfection Method | |
| BR102021018675A2 (en) | LIQUID OZONIZATION SYSTEM AND ITS USES | |
| Singh et al. | Sterilization of pharmaceutical dosage forms | |
| Kremer et al. | STERILIZATION CENTRAL: COVID-19, Processing, and the Importance of Definitions: Focus on Face Masks | |
| Gupta | STERILIZATION AND DISINFECTION |